Targeting the eicosanoid pathway in non-small-cell lung cancer

Expression and purification of human mPGES-1 in E. coli and identification of inhibitory compounds from a drug-library

(2011) Woo-Il Kim et al.   BMB Reports

Phase II Study of Celecoxib and Docetaxel in Non-small Cell Lung Cancer (NSCLC) Patients with Progression after Platinum-Based Therapy

(2010) Bryan J. Schneider et al.   Journal of Thoracic Oncology

Phase II Study of Docetaxel and Celecoxib, a Cyclooxygenase-2 Inhibitor, in Elderly or Poor Performance Status (PS2) Patients with Advanced Non-small Cell Lung Cancer

(2010) Shirish M. Gadgeel et al.   Journal of Thoracic Oncology

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Epidermal growth factor receptor immunohistochemistry

(2008) Fred R. Hirsch et al.   CANCER

Focusing Downstream in Lung Cancer Prevention: 15-Hydroxyprostaglandin Dehydrogenase

(2008) S. M. Dubinett et al.   Cancer Prevention Research

NAD+-Dependent 15-Hydroxyprostaglandin Dehydrogenase Regulates Levels of Bioactive Lipids in Non-Small Cell Lung Cancer

(2008) D. Hughes et al.   Cancer Prevention Research

15-Hydroxyprostaglandin Dehydrogenase is a Target of Hepatocyte Nuclear Factor 3  and a Tumor Suppressor in Lung Cancer

(2008) G. Huang et al.   CANCER RESEARCH

The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib

(2008) M. J. Fidler et al.   CLINICAL CANCER RESEARCH

Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin

(2008) G. D. Girnun et al.   CLINICAL CANCER RESEARCH

Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis

(2008) Jing Yang et al.   DEVELOPMENTAL CELL

Novel Strategies for the Treatment of Lung Cancer: Modulation of Eicosanoids

(2008) Michael G. Backlund et al.   JOURNAL OF CLINICAL ONCOLOGY

Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy—Cancer and Leukemia Group B Trial 30203

(2008) Martin J. Edelman et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group

(2008) Anuj Agarwala et al.   Journal of Thoracic Oncology

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance

(2008) Kostyantyn Krysan et al.   Journal of Thoracic Oncology

Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial

(2008) John A Baron et al.   LANCET

The hippocratic finger points the blame at PGE2

(2008) Kenneth G Coggins et al.   NATURE GENETICS

Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy

(2008) Sandeep Uppal et al.   NATURE GENETICS

Human Microsomal Prostaglandin E Synthase-1 (mPGES-1) Binding with Inhibitors and the Quantitative Structure−Activity Correlation

(2007) Mohamed Diwan M. AbdulHameed et al.   Journal of Chemical Information and Modeling